Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.56 |
| ▸ | CASP3 | P42574 | 2/20 | 0.53 |
| ▸ | TLR2 | O60603 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21639208 | 1.00 | MDM4 (0.58) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL8426773 | 0.91 | MDM2 (0.58) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL25357928 | 0.90 | MDM4 (0.60) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL21639432 | 0.90 | MDM4 (0.60) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL31427181 | 0.90 | MDM4 (0.60) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL18191950 | 0.90 | MDM4 (0.60) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL31348872 | 0.90 | MDM4 (0.60) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL26008763 | 0.89 | MDM4 (0.49) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL21978277 | 0.89 | MDM4 (0.59) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL8892538 | 0.89 | MDM2 (0.60) | MDM4TP53MDM2CASP3TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024098039-A2 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20230406885-A1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2023-12-21 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| CN-110475785-B | Peptide compound, method for producing same, composition for screening, and method for selecting peptide compound | 富士胶片株式会社 | 2023-06-13 | — | — | CN | disclosed |
| US-11319347-B2 | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound | FUJIFILM CORPORATION (JP) | 2022-05-03 | — | — | US | disclosed |
| US-20200040039-A1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | FUJIFILM CORPORATION (JP) | 2020-02-06 | — | — | US | disclosed |
| EP-3604326-A1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | FUJIFILM Corporation (JP) | 2020-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406885-A1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | IL1A, IL1B, IL1R1 | MDM4 4837/4885TP53 3017/4885MDM2 4355/4885 |
| US-20200040039-A1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | VIP, NPPA, NGLY1 | MDM4 4154/4885TP53 1409/4885MDM2 4758/4885 |
| US-11319347-B2 | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound | VIP, NPPA, NGLY1 | MDM4 4154/4885TP53 1409/4885MDM2 4758/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | MDM4 1648/4885TP53 614/4885MDM2 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.